Sweeping data integration and clinical trial simulations are needed to help decide which targets to prioritize in researching new tuberculosis treatment regimens.
A new grant will help support Vanderbilt’s RePORT Brazil, one of an international consortium’s six regional tuberculosis research programs.
Drug-resistant tuberculosis is on the rise, and novel antibacterial drugs called SPTs have potential for treating the deadly lung infection.
The National Institutes of Health has awarded a five-year, $5 million grant to Vanderbilt University Medical Center for continued support of the Brazil Regional Prospective Observational Research in Tuberculosis network, or RePORT-Brazil.
Vanderbilt’s Kelly Dooley, MD, PhD, MPH, recently received the Research in Action Award from the Treatment Action Group (TAG).
Vanderbilt University Medical Center is set to construct a state-of-the-art BioSafety Level 3 (BSL3) facility for research involving the COVID-19 virus, anthrax and other dangerous microorganisms.
Accessibility Tools